StockData
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc. (COYA) stock

COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.09+0.07 (+2.32%)

Close on Nov 18, 2026Market cap $72.48MP/E –Yield –

Coya Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Coya Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $4.69M, up 17.6% year over year. For fiscal 2025 it was $7.95M, up 123.6% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.95M+123.6%
FY2024Dec 31, 2024$3.55M-40.8%
FY2023Dec 31, 2023$6.00M–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$234.13K-93.4%
Q2 FY2026Jun 30, 2026$243.75K+49.0%
Q1 FY2026Mar 31, 2026$251.15K-2.6%
Q4 FY2025Dec 31, 2025$3.96M+202768.8%
Q3 FY2025Sep 30, 2025$3.56M–
Q2 FY2025Jun 30, 2025$163.62K-95.2%
Q1 FY2025Mar 31, 2025$257.88K+103.3%
Q4 FY2024Dec 31, 2024$1.95K-100.0%
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$3.43M–
Q1 FY2024Mar 31, 2024$126.84K–
Q4 FY2023Dec 31, 2023$6.00M–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0–

More Coya Therapeutics figures

See a number that looks wrong?